Kissei

Kissei, also known as Kissei Pharmaceutical, is a pharmaceutical company based in Matsumoto, Nagano, Japan. The company is associated with the discovery or development of medicines across several therapeutic areas, including renal disease, oncology, metabolic disorders, urology, and allergy-related conditions. Its identified products and development programs include difelikefalin, fostamatinib, linzagolix, mitiglinide, remogliflozin etabonate, silodosin, and tranilast. Kissei’s portfolio illustrates a research-oriented pharmaceutical model that combines internally discovered or developed medicines with regional licensing and commercialization arrangements. Its products include both marketed therapies and compounds whose development or commercialization has involved collaboration with other pharmaceutical or biotechnology companies. The company’s work has included treatments for chronic kidney disease-related symptoms, inflammatory and allergic conditions, diabetes, urinary-tract disorders, and reproductive-health indications. A notable international transaction was announced in March 2020, when Kissei and CG Oncology, Inc. entered an exclusive license, development, and commercialization agreement for CG0070, an oncolytic immunotherapy drug. The agreement covered Japan, South Korea, Taiwan, and other Asian territories, while excluding China. This arrangement expanded Kissei’s role beyond its domestic Japanese base and connected the company with an emerging cancer-immunotherapy program. Kissei is best understood as a research-based Japanese pharmaceutical brand rather than a consumer-facing healthcare label. Its identity is centered on prescription medicines, clinical development, regulatory commercialization, and partnerships in selected Asian markets. Publicly available reference material supplied for this entry does not establish a founding year, founder, ownership structure, current executives, listing details, official website, or a complete account of present-day sales and geographic operations.

Kissei is a Japanese pharmaceutical company headquartered in Matsumoto, Nagano. The available reference material presents the company primarily through its pharmaceutical research, development, and commercialization activities rather than through a detailed corporate chronology. Kissei’s identified portfolio spans multiple therapeutic fields, including kidney disease, urology, diabetes, oncology, inflammatory and allergic disorders, and reproductive health. The company’s product and development history includes several medicines that have been discovered or developed by Kissei. Difelikefalin is associated with treatment of kidney-disease-related conditions. Fostamatinib, marketed under the trade name Tavalisse, is another product in the company’s identified portfolio. Linzagolix represents a reproductive-health development, while mitiglinide, marketed as Glufast, and remogliflozin etabonate are associated with diabetes treatment. Silodosin, marketed as Urief, is a urology medicine, and tranilast, marketed as Rizaben, is associated with anti-inflammatory or antiallergic treatment. Kissei’s activities also include external partnerships and regional commercialization arrangements. In March 2020, the company and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement covering CG0070, described as an oncolytic immunotherapy drug. The territorial scope included Japan, South Korea, Taiwan, and other Asian countries, but specifically did not include China. The agreement is significant because it shows Kissei pursuing access to an oncology platform through collaboration with a biotechnology company, while retaining a defined regional role in development and commercialization. The supplied sources do not provide enough verified information to reconstruct Kissei’s full founding history, leadership succession, ownership, financial performance, manufacturing footprint, or current product-by-product regulatory status. Accordingly, this dossier focuses on the products and 2020 regional licensing event directly supported by the reference material and avoids attributing unsupported dates or corporate milestones.

• 2020

  Regional CG0070 agreement announced

  [1]Kisseien.wikipedia.org

  Kissei and CG Oncology announced an exclusive license, development, and commercialization agreement for CG0070 in Japan, South Korea, Taiwan, and other Asian countries, excluding China.

A Japanese research-based pharmaceutical company focused on prescription medicines, drug development, and selected regional licensing and commercialization partnerships.

• Renal medicine

  Difelikefalin

  Difelikefalin is one of the medicines identified as discovered or developed by Kissei. The supplied reference places it within Kissei’s pharmaceutical portfolio, but does not provide detailed information on its specific indication, regulatory status, markets, or commercialization arrangements.

• Prescription medicine

  Fostamatinib

  Fostamatinib is listed among Kissei’s discovered or developed products and is identified with the trade name Tavalisse. The available source does not specify the extent of Kissei’s role in its development or the markets in which the product is commercialized.

• Women's health medicine

  Linzagolix

  Linzagolix is listed among Kissei’s discovered or developed pharmaceutical products. The supplied reference does not give further information about its indication, launch timing, or market status.

• Diabetes medicine

  Mitiglinide

  Mitiglinide, marketed under the trade name Glufast, is identified as a Kissei-discovered or developed medicine. It is associated with diabetes treatment, although the supplied reference does not provide detailed information about its current availability or geographic scope.

• Diabetes medicine

  Remogliflozin etabonate

  Remogliflozin etabonate is included in the list of medicines discovered or developed by Kissei. The available material does not establish its launch year, approved indications, or current commercialization status.

• Urology medicine

  Silodosin

  Silodosin, marketed under the trade name Urief, is one of Kissei’s identified pharmaceutical products. It represents the company’s urology portfolio, although the supplied source does not provide a full history of its development, approvals, or markets.

• Anti-inflammatory and antiallergic medicine

  Tranilast

  Tranilast, marketed under the trade name Rizaben, is listed among medicines discovered or developed by Kissei. The available reference does not specify its current indications, launch date, or geographical availability.

• Oncolytic immunotherapy

  CG0070

  CG0070 is an oncolytic immunotherapy drug covered by Kissei’s 2020 exclusive license, development, and commercialization agreement with CG Oncology. The arrangement covered Japan, South Korea, Taiwan, and other Asian countries, excluding China. The supplied material does not establish the program’s subsequent regulatory or commercial outcome.

• 2026

  France recalls Tavneos batches after deaths linked in Japan

  France's medicine safety agency ANSM said the recall of all Tavneos batches available in France would begin on August 19, after the drug, made by U.S. biotech firm Amgen and sold by partner companies worldwide, was linked to 20 deaths in Japan. The European Commission had revoked the drug's marketing authorisation earlier in the month.

  Source

Read more

• 2020

  Exclusive regional license and development agreement for CG0070M&A

  Background

  Kissei sought a regional role in the development and commercialization of CG0070, an oncolytic immunotherapy drug associated with CG Oncology.

  Action taken

  Kissei and CG Oncology entered an exclusive license, development, and commercialization agreement covering Japan, South Korea, Taiwan, and other Asian countries, with China excluded from the territory.

  Aftermath

  The supplied reference does not provide verified details about later clinical, regulatory, or commercial results.

  Source

• 2020

  Kissei and CG Oncology announce regional agreement for CG0070[1]Kisseien.wikipedia.org

  M&A · Other

  Kissei and CG Oncology announced an exclusive license, development, and commercialization agreement for CG0070, an oncolytic immunotherapy drug. The territory included Japan, South Korea, Taiwan, and other Asian countries, but excluded China.

1. 1Kisseien.wikipedia.org
2. 2France recalls Tavneos batches after deaths linked in Japanthehindu.com